EU Approves AstraZeneca's COVID-19 Vaccine Vaxzevria as Adult Booster
On May 23, AstraZeneca said its new crown vaccine Vaxzevria had been approved by the European Medicines Agency (EMA) as a booster vaccine for adults. Last Thursday, AstraZeneca's new crown vaccine booster (clinical trial data) received a positive assessment from the CHMP (European Committee for Medicinal Products for Human Use).
It is reported that the vaccine can be used as a booster for the first two doses of the Vaxzevria new crown vaccine, and can also be used as a booster for other mRNA new crown vaccines produced by companies such as Pfizer (PFE.US)/BioNTech (BNTX.US) or Moderna (MRNA.US). Strengthen the needle.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-01
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
AstraZeneca to Invest $2.5 Billion to Establish Global Drug R&D Center in Beijing
-
AstraZeneca to invest $3.5 billion in the United States
-
Ascending to the Summit: AstraZeneca Crowned as the Most Competitive MNC in China
-
Restructuring at AstraZeneca China: Leadership Changes and New Business Division
-
Bristol Myers Squibb's Acquisition Spree: Will it Boost its Cancer Drug Portfolio?
-
Is AstraZeneca's Acquisition of Gracell Biotechnologies a Game-Changer for Cell Therapy and Expansion in China?
-
FDA Approves Wainua, a Breakthrough Treatment for Rare Genetic Disease-Related Polyneuropathy
-
AstraZeneca Acquires Icosavax in $1.1 Billion Deal to Enter the RSV Vaccine Market
Recommend Reading
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
BASF Sells Coatings Business for €7.7 Billion, Forming Independent Company with Carlyle
-
Premium Global Chemical Sourcing Requests (17-21 Nov 2025)
-
Fipronil: Uses, Safety, and Environmental Impact
-
Ethylene Glycol: Production, Uses, and Safety
-
Geopolitical and Supply Disruptions Bring Positive Impact, Oil Prices Jump Nearly 3% on Friday